Showing 1411-1420 of 5771 results for "".
- Ocular Therapeutix Announces First Subjects Screened in Phase 3 Clinical Trial of Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-first-subjects-screened-in-phase-3-pivotal-clinical-trial-of-axpaxli-in-wet-amd/2482113/Ocular Therapeutix announced that the first three subjects have been screened and received their first aflibercept injection in the phase 3 SOL-1 clinical trial of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related macular degenerati
- EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restorethttps://modernod.com/news/eyebio-announces-positive-visual-anatomic-and-safety-data-from-first-in-human-ph1b2a-amarone-trial-of-restoret/2482112/Eyebiotech announced the presentation of Week 12 data from its first-in-human phase 1b/2a AMARONE trial of Restoret in patients with treatment-naïve diabetic macular edema (DME) and treatment-naïve wet age-related macular degeneration (AMD). The analysis was presented by Charles C.
- Adverum Announces Positive Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMDhttps://modernod.com/news/adverum-biotechnologies-announces-positive-preliminary-efficacy-and-safety-data-from-luna-phase-2-trial-of-ixo-vec-in-patients-with-wet-amd/2482107/Adverum Biotechnologies announced preliminary safety and efficacy data from the ongoing LUNA phase 2 trial in patients with wet age-related macular degeneration (AMD). These data are being presented by Arshad Khanani, MD, today at the 47th Annual Meeting of the Macula Society. The presentation, t
- Beacon Therapeutics Announces Positive 12-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with XLRPhttps://modernod.com/news/beacon-therapeutics-announces-positive-12-month-data-from-phase-2-skyline-trial-of-agtc-501-in-patients-with-xlrp/2482105/Beacon Therapeutics announced the presentation of 12-month interim safety and efficacy results for the phase 2 SKYLINE trial in patients with X-linked retinitis pigmentosa (XLRP) at the Macula Society Meeting in Palm Springs, California. Twelve-month data from males with XLRP
- Nicox Announces Presentations at the Upcoming ARVO Annual Meeting 2024https://modernod.com/news/nicox-announces-presentations-at-the-upcoming-arvo-annual-meeting-2024/2482100/Nicox SA announced presentations on NCX 470 and NCX 1728 at the upcoming Association for Research in Vision and Ophthalmology (ARVO) annual meeting, May 5-9, 2024 in Seattle. Abstract/Presentation Title: Tolerability and intraocular pressure (IOP)-lowering efficacy
- Bausch + Lomb to Present Scientific Data and Analyses on Xipere at Macula Society Annual Meetinghttps://modernod.com/news/bausch-lomb-to-present-scientific-data-and-analyses-on-xipere-at-macula-society-annual-meeting/2482098/Bausch + Lomb announced it will feature two podium presentations on Xipere during the Macula Society annual meeting, which will take place in Palm Springs, California, Feb. 7-10, 2024. One presentation will highlight the results of a study assessing the durability of Xipe
- Aviceda Announces First Patient Dosed in Part 2 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for GAhttps://modernod.com/news/aviceda-therapeutics-announces-first-patient-dosed-in-part-2-of-the-phase-23-siglec-trial-assessing-avd-104-for-ga/2482092/Aviceda Therapeutics announced it has dosed the first patient in part 2 of the phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “Based on the efficacy and safety we saw in part 1, we moved rapidly to i
- OcuCell Announces Funding From the Eye Bank Association of Americahttps://modernod.com/news/ocucell-announces-funding-from-the-eye-bank-association-of-america/2482084/OcuCell has announced funding from the Eye Bank Association of America (EBAA). Financial terms were not disclosed. Founded in 1961, EBAA member banks have provided over 2,000,000 corneal transplants. OcuCell says the partnership will enable the company to have a connecti
- Ocular Therapeutix Announces FDA Agreement to Amend SPA for Clinical Trial of Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-fda-agreement-to-amend-spa-for-clinical-trial-of-axpaxli-in-wet-amd/2482079/Ocular Therapeutix announced that the FDA has agreed to a special protocol assessment (SPA) agreement modification for the company’s pivotal phase 3 SOL clinical trial of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related
- Inflammasome Therapeutics Announces First Patient Dosed in Phase 1 DME Study of the Dual Inflammasome Inhibitor K8https://modernod.com/news/inflammasome-therapeutics-announces-first-patient-dosed-in-phase-1-dme-study-of-the-dual-inflammasome-inhibitor-k8/2482069/Inflammasome Therapeutics announced the first patient has been dosed in a phase 1 study of a novel compound in the treatment of diabetic macular edema (DME). The 24-week study (ClinicalTrials.gov ID NCT05699759) is designed to assess safety and initial evidence of efficacy. Th